JP7546549B2 - 組み合わせ療法 - Google Patents
組み合わせ療法 Download PDFInfo
- Publication number
- JP7546549B2 JP7546549B2 JP2021513254A JP2021513254A JP7546549B2 JP 7546549 B2 JP7546549 B2 JP 7546549B2 JP 2021513254 A JP2021513254 A JP 2021513254A JP 2021513254 A JP2021513254 A JP 2021513254A JP 7546549 B2 JP7546549 B2 JP 7546549B2
- Authority
- JP
- Japan
- Prior art keywords
- kras
- inhibitor
- formula
- pharmaceutical composition
- dasatinib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024091743A JP2024133475A (ja) | 2018-09-10 | 2024-06-05 | 組み合わせ療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729169P | 2018-09-10 | 2018-09-10 | |
| US62/729,169 | 2018-09-10 | ||
| PCT/US2019/050224 WO2020055755A1 (en) | 2018-09-10 | 2019-09-09 | Combination therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091743A Division JP2024133475A (ja) | 2018-09-10 | 2024-06-05 | 組み合わせ療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500381A JP2022500381A (ja) | 2022-01-04 |
| JP2022500381A5 JP2022500381A5 (cg-RX-API-DMAC7.html) | 2022-09-16 |
| JP7546549B2 true JP7546549B2 (ja) | 2024-09-06 |
Family
ID=69776771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513254A Active JP7546549B2 (ja) | 2018-09-10 | 2019-09-09 | 組み合わせ療法 |
| JP2024091743A Pending JP2024133475A (ja) | 2018-09-10 | 2024-06-05 | 組み合わせ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091743A Pending JP2024133475A (ja) | 2018-09-10 | 2024-06-05 | 組み合わせ療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220040181A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4552631A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7546549B2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3849534T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3017461T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3849534T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20250480T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE071715T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3849534T (cg-RX-API-DMAC7.html) |
| PL (1) | PL3849534T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3849534T (cg-RX-API-DMAC7.html) |
| RS (1) | RS66727B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3849534T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020055755A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3112043A1 (en) * | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| US12208099B2 (en) * | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| CN114616232B (zh) * | 2019-09-06 | 2026-05-05 | 正大天晴药业集团南京顺欣制药有限公司 | 氮杂环庚烷并嘧啶类衍生物及其医药用途 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| BR112022006394A2 (pt) | 2019-10-02 | 2022-07-26 | Tolremo Therapeutics Ag | Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer |
| US20230257374A1 (en) * | 2019-10-10 | 2023-08-17 | Innovent Biologics (Suzhou) Co., Ltd. | Novel kras g12c protein inhibitor, preparation method therefor, and use thereof |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| WO2021108682A1 (en) | 2019-11-27 | 2021-06-03 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| TW202144349A (zh) * | 2020-04-30 | 2021-12-01 | 大陸商上海科州藥物研發有限公司 | 作為kras抑制劑的雜環化合物的製備及其應用方法 |
| WO2021231526A1 (en) * | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
| CN113683616B (zh) * | 2020-05-18 | 2025-12-30 | 广州百霆医药科技有限公司 | Kras g12c突变蛋白抑制剂 |
| WO2021260110A1 (en) | 2020-06-25 | 2021-12-30 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease |
| AU2021298154A1 (en) * | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| CA3212085C (en) | 2021-04-07 | 2025-02-11 | Tolremo Therapeutics Ag | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR RELIEF OF CANCER |
| CN113429405A (zh) * | 2021-06-10 | 2021-09-24 | 都创(上海)医药开发有限公司 | Mrtx849化合物的晶型及其制备方法和用途 |
| CN117940132A (zh) * | 2021-06-24 | 2024-04-26 | 医睿世康药业研发公司 | Erk1/2和kras g12c抑制剂组合疗法 |
| WO2023283213A1 (en) | 2021-07-07 | 2023-01-12 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| CA3224841A1 (en) | 2021-07-14 | 2023-01-19 | Zhenwu Li | Tricyclic compounds as inhibitors of kras |
| CA3229855A1 (en) | 2021-08-31 | 2023-03-09 | Incyte Corporation | Naphthyridine compounds as inhibitors of kras |
| KR20240114793A (ko) | 2021-11-05 | 2024-07-24 | 프론티어 메디슨즈 코포레이션 | Kras g12c 억제제 |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
| CN119607214B (zh) * | 2025-02-17 | 2025-06-20 | 四川大学华西医院 | Src抑制剂联合kras-g12c抑制剂用于制备治疗kras-g12c突变型肺癌的药物中的应用及药物组合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017528488A (ja) | 2014-09-18 | 2017-09-28 | アラクセス ファーマ エルエルシー | がんの処置のための併用療法 |
| WO2017201161A1 (en) | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2452603A1 (en) | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| US20040014676A1 (en) | 2001-07-09 | 2004-01-22 | Ramalinga Dharanipragada | SRC kinase inhibitors useful for treating osteoporosis |
| EP2258371A1 (en) | 2001-08-10 | 2010-12-08 | Novartis AG | Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia |
| RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| US8283441B2 (en) | 2006-10-31 | 2012-10-09 | University Of Toledo | Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases |
| CN101677979A (zh) | 2007-04-19 | 2010-03-24 | 利奥制药有限公司 | Src家族激酶抑制剂 |
| CN104230901A (zh) | 2008-09-15 | 2014-12-24 | 加利福尼亚大学董事会 | 用于调节ire1、src和abl活性的方法和组合物 |
| US9090617B1 (en) | 2011-08-03 | 2015-07-28 | National Taiwan University | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
| PL2739139T3 (pl) | 2011-08-03 | 2020-06-15 | National Taiwan University | Agoniści białkowej fosfatazy tyrozynowej 1 zawierającej domeny homologii z src 2 i sposoby leczenia z ich zastosowaniem |
| CA2944198C (en) | 2013-04-26 | 2021-11-16 | Indiana University Research & Technology Corporation | Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2) |
| US9862701B2 (en) * | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| JP7327802B2 (ja) * | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法 |
| CA3082579A1 (en) | 2017-11-15 | 2019-05-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
-
2019
- 2019-09-09 WO PCT/US2019/050224 patent/WO2020055755A1/en not_active Ceased
- 2019-09-09 EP EP25153820.3A patent/EP4552631A3/en active Pending
- 2019-09-09 FI FIEP19858883.2T patent/FI3849534T3/fi active
- 2019-09-09 SI SI201930915T patent/SI3849534T1/sl unknown
- 2019-09-09 ES ES19858883T patent/ES3017461T3/es active Active
- 2019-09-09 RS RS20250386A patent/RS66727B1/sr unknown
- 2019-09-09 HR HRP20250480TT patent/HRP20250480T1/hr unknown
- 2019-09-09 US US17/275,175 patent/US20220040181A1/en not_active Abandoned
- 2019-09-09 LT LTEPPCT/US2019/050224T patent/LT3849534T/lt unknown
- 2019-09-09 HU HUE19858883A patent/HUE071715T2/hu unknown
- 2019-09-09 PL PL19858883.2T patent/PL3849534T3/pl unknown
- 2019-09-09 JP JP2021513254A patent/JP7546549B2/ja active Active
- 2019-09-09 EP EP19858883.2A patent/EP3849534B1/en active Active
- 2019-09-09 DK DK19858883.2T patent/DK3849534T3/da active
- 2019-09-09 PT PT198588832T patent/PT3849534T/pt unknown
-
2024
- 2024-06-05 JP JP2024091743A patent/JP2024133475A/ja active Pending
-
2025
- 2025-03-18 US US19/082,614 patent/US20250213579A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017528488A (ja) | 2014-09-18 | 2017-09-28 | アラクセス ファーマ エルエルシー | がんの処置のための併用療法 |
| WO2017201161A1 (en) | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| PL3849534T3 (pl) | 2025-05-12 |
| LT3849534T (lt) | 2025-05-12 |
| EP3849534A1 (en) | 2021-07-21 |
| EP4552631A3 (en) | 2025-07-02 |
| JP2022500381A (ja) | 2022-01-04 |
| US20220040181A1 (en) | 2022-02-10 |
| JP2024133475A (ja) | 2024-10-02 |
| HUE071715T2 (hu) | 2025-09-28 |
| WO2020055755A1 (en) | 2020-03-19 |
| EP3849534A4 (en) | 2022-06-22 |
| DK3849534T3 (da) | 2025-05-19 |
| SI3849534T1 (sl) | 2025-05-30 |
| FI3849534T3 (fi) | 2025-05-15 |
| ES3017461T3 (en) | 2025-05-13 |
| PT3849534T (pt) | 2025-04-01 |
| US20250213579A1 (en) | 2025-07-03 |
| EP3849534B1 (en) | 2025-03-05 |
| HRP20250480T1 (hr) | 2025-06-20 |
| RS66727B1 (sr) | 2025-05-30 |
| EP4552631A2 (en) | 2025-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024133475A (ja) | 組み合わせ療法 | |
| JP2025098159A (ja) | 組み合わせ療法 | |
| JP2025000632A (ja) | 組み合わせ療法 | |
| JP7546548B2 (ja) | 組み合わせ療法 | |
| JP2025000629A (ja) | 組み合わせ療法 | |
| JP2025000630A (ja) | 組み合わせ療法 | |
| JP2024540839A (ja) | Kras g12d阻害剤とshp-2阻害剤との併用療法 | |
| JP2024537140A (ja) | Kras g12d阻害剤とsos1阻害剤との併用療法 | |
| JP2024537136A (ja) | KRAS G12D阻害剤と汎ErbBファミリー阻害剤との併用療法 | |
| JP2024521788A (ja) | 併用療法 | |
| JP2025512999A (ja) | Sos1阻害剤及びegfr阻害剤を含む併用療法 | |
| US20250177399A1 (en) | Combination therapies | |
| JP2025513802A (ja) | Sos1阻害剤及びmek阻害剤を含む併用療法 | |
| JP2025531491A (ja) | 併用療法 | |
| HK40109896A (en) | Combination therapies of kras g12d inhibitors with shp-2 inhibitors | |
| HK40109895A (en) | Combination therapies of kras g12d inhibitors with sos1 inhibitors | |
| EA044829B1 (ru) | Способы комбинированной терапии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220908 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220908 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231107 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240605 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240606 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240626 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240806 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240827 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7546549 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |